Compare Stocks → Bitcoin Rockets To Record High But Buy THIS Instead (From Paradigm Press) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:BPTHNASDAQ:CLSNNASDAQ:ITRMNASDAQ:UMRXNASDAQ:VVUS Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBPTHBio-Path$4.29+2.1%$5.40$2.70▼$44.80$2.91M0.351.16 million shs2.14 million shsCLSNImunon$2.22$1.80▼$15.75$13.91M2.27150,471 shs711 shsITRMIterum Therapeutics$1.43$1.51$0.62▼$2.50$23.50M2.36523,775 shs59,817 shsUMRXCogent Biosciences$6.71+1.5%$10.50$0.29▼$3.72$284.97M3.931.22 million shs1.52 million shsVVUSVIVUS$0.37$0.44▼$4.75$7.33M-0.841.44 million shs2.03 million shsThe 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBPTHBio-Path+2.14%+40.66%-3.81%-47.30%-85.16%CLSNImunon0.00%0.00%0.00%0.00%0.00%ITRMIterum Therapeutics0.00%-9.49%-9.49%-24.74%+20.17%UMRXCogent Biosciences+1.51%+2.44%-1.76%+46.19%-39.55%VVUSVIVUS0.00%0.00%0.00%0.00%0.00%Did You Get Your Free Bitcoin Yet? (Ad)And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.>> Register right hereMarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBPTHBio-Path1.4779 of 5 stars3.52.00.00.02.80.00.6CLSNImunonN/AN/AN/AN/AN/AN/AN/AN/AITRMIterum Therapeutics0.8502 of 5 stars3.52.00.00.00.60.00.6UMRXCogent BiosciencesN/AN/AN/AN/AN/AN/AN/AN/AVVUSVIVUSN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBPTHBio-Path3.00Buy$40.00832.40% UpsideCLSNImunonN/AN/AN/AN/AITRMIterum Therapeutics3.00Buy$6.00319.58% UpsideUMRXCogent BiosciencesN/AN/AN/AN/AVVUSVIVUSN/AN/AN/AN/ACurrent Analyst RatingsLatest BPTH, CLSN, UMRX, ITRM, and VVUS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/18/2024BPTHBio-PathRoth MkmSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$40.004/1/2024ITRMIterum TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$6.003/27/2024BPTHBio-PathRoth MkmSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$12.00 ➝ $40.003/6/2024ITRMIterum TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$6.002/7/2024ITRMIterum TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$6.00(Data available from 4/20/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBPTHBio-PathN/AN/AN/AN/A$0.71 per shareN/ACLSNImunon$500K0.00N/AN/A$9.66 per share0.00ITRMIterum TherapeuticsN/AN/AN/AN/A($0.48) per shareN/AUMRXCogent Biosciences$22.50M12.67N/AN/A$1.04 per share6.45VVUSVIVUS$69.76M0.00N/AN/A($6.50) per share0.00Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBPTHBio-Path-$16.08M-$40.80N/AN/AN/AN/A-375.74%-248.63%5/10/2024 (Estimated)CLSNImunon-$20.77MN/A0.00N/AN/A-5,229.80%-50.18%-36.94%N/AITRMIterum Therapeutics-$38.37M-$2.97N/AN/AN/AN/A-664.00%-87.64%5/10/2024 (Estimated)UMRXCogent Biosciences-$31.83M-$1.04N/AN/AN/A-96.84%-87.78%-52.14%N/AVVUSVIVUS-$31.50M-$2.96N/AN/AN/A-39.28%N/A-12.18%N/ALatest BPTH, CLSN, UMRX, ITRM, and VVUS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/8/202412/31/2023BPTHBio-Path-$5.40-$5.40N/AN/AN/AN/A DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBPTHBio-PathN/AN/AN/AN/AN/ACLSNImunonN/AN/AN/AN/AN/AITRMIterum TherapeuticsN/AN/AN/AN/AN/AUMRXCogent BiosciencesN/AN/AN/AN/AN/AVVUSVIVUSN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBPTHBio-PathN/A1.601.60CLSNImunon0.136.526.52ITRMIterum Therapeutics3.631.891.89UMRXCogent Biosciences0.182.902.90VVUSVIVUSN/A0.430.28OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBPTHBio-Path5.74%CLSNImunon12.97%ITRMIterum Therapeutics9.21%UMRXCogent Biosciences26.39%VVUSVIVUS7.32%Insider OwnershipCompanyInsider OwnershipBPTHBio-Path3.05%CLSNImunon4.66%ITRMIterum Therapeutics5.40%UMRXCogent Biosciences31.50%VVUSVIVUS12.00%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableBPTHBio-Path10679,000658,000OptionableCLSNImunon277.10 million6.77 millionOptionableITRMIterum Therapeutics1416.43 million15.54 millionNot OptionableUMRXCogent Biosciences7242.47 millionN/ANot OptionableVVUSVIVUS5717.87 millionN/AOptionableBPTH, CLSN, UMRX, ITRM, and VVUS HeadlinesSourceHeadlineVIVUS Provides Update on Pipeline and Program Milestonesmarkets.businessinsider.com - January 8 at 10:04 AMShark research group to build new global headquarters in Jacksonville with help from state fundingactionnewsjax.com - June 26 at 9:16 AMMetaview announces Answers, the world's first conversational AI for the interview processit.tmcnet.com - May 25 at 11:10 AMPancrelipase (CAS 53608-75-6) Market 2023 | Industry Growth ... - StreetBuzznews.google.com - May 12 at 2:58 AMExploring Huge Demand of Peripherally Acting Anti-Obesity Drug ... - Digital Journalnews.google.com - May 12 at 2:58 AMExtensive Growth Opportunities to be Witnessed by Prescription Weight-Loss Pills Market 2023 Analysis of Risin - openPRnews.google.com - May 11 at 8:54 AMErectile Dysfunction Drugs Market to Register High Demand Rate by ... - Cottonwood Holladay Journalnews.google.com - May 11 at 8:54 AMMilestone Pharmaceuticals Reports First Quarter 2023 Financial ... - PR Newswirenews.google.com - May 11 at 8:54 AMAnti-obesity Therapeutics Market to Witness the Highest Growth ... - Cottonwood Holladay Journalnews.google.com - May 11 at 3:54 AMAnti Obesity Drugs Market Future Industry Scope for New ... - Digital Journalnews.google.com - May 11 at 3:54 AMThis Crazy Six-Wheel Hatchback by Briggs & Stratton Was One of ... - autoevolutionnews.google.com - May 10 at 12:51 PMProstatic Artery Embolization Market Current and Upcoming Projects ... - Digital Journalnews.google.com - May 9 at 6:48 AMThis 1899 Porsche Pioneered Rivian's Quad-Motor Drive, Ram ... - MotorBiscuitnews.google.com - May 7 at 8:20 PMPorsche Pioneered the Range-Extended EV 100+ Years Before ... - MotorBiscuitnews.google.com - May 6 at 3:22 PMIncreasing Opportunities In Peripherally Acting Anti-Obesity Drug Market Latest Trends, Technological Advancem - openPRnews.google.com - May 5 at 1:45 PMNonalcoholic Steatohepatitis Treatment Market Outlook Growths ... - Digital Journalnews.google.com - May 5 at 7:44 AMA Big Fat Problem: Will children in the UK be given weight-loss injections? - Firstpostnews.google.com - May 2 at 10:24 AMIntraoperative Ultrasound Market Latest Trends, Techniques and Applications|2023-2030 - openPRnews.google.com - April 28 at 9:38 AMBuild Your Own Case Study | Obesity: Treating the Whole Patient - Healionews.google.com - April 27 at 8:14 PMBladder Cancer Market Demand in Various industries and Significant for Various Regions|2023-2030 - openPRnews.google.com - April 27 at 3:10 PMPediatric Obesity Management Market is projected to grow with a 4 ... - Future Market Insightsnews.google.com - April 27 at 10:10 AMGlobal Erectile Dysfunction Drugs Market Analysis by Recent Trends, Development, Regional Growth Overview and - openPRnews.google.com - April 26 at 7:33 AMNon-Alcoholic Steatohepatitis (NASH) Market Analysis, Trends, Growth, Research And Forecast 2032 - openPRnews.google.com - April 25 at 2:02 AMWhat to Know About Obesity and Bone Health - Health Centralnews.google.com - April 24 at 4:02 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsBio-PathNASDAQ:BPTHBio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. It is also developing Liposomal Bcl-2 (BP1002) for the treatment of refractory/relapsed lymphoma and chronic lymphocytic leukemia; Liposomal STAT3 (BP1003) for the treatment of pancreatic cancer, non-small cell lung cancer, and AML; and BP1001-A for the treatment of solid tumors. Bio-Path Holdings, Inc. was founded in 2007 and is based in Bellaire, Texas.ImunonNASDAQ:CLSNCelsion Corporation, a clinical stage biotechnology company, focuses on the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies. Its product pipeline includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer; and ThermoDox, a proprietary heat-activated liposomal encapsulation of doxorubicin, which is in development stage for various cancer indications. The company also has two feasibility stage platform technologies for the development of nucleic acid-based immunotherapies, vaccines, and other anti-cancer DNA or RNA therapies. Celsion Corporation was founded in 1982 and is based in Lawrenceville, New Jersey.Iterum TherapeuticsNASDAQ:ITRMIterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.Cogent BiosciencesNASDAQ:UMRXCogent Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immunotherapy products designed to harness the power of a patient's immune system to cure cancer. The firm's technologies include Antibody-Coupled T-cell Receptor, which is a chimeric protein that binds to tumor targeting antibodies. The company was founded by Charles Wilson and Dario Campana in March 2014 and is headquartered in Cambridge, MA.VIVUSNASDAQ:VVUSVIVUS, Inc. engages in the development and commercialization of novel therapeutic products. The firm's products are indicated for the treatment of obese and overweight patients, exocrine pancreatic insufficiency, and erectile dysfunction. Its products include PANCREAZE, Qsymia, and STENDRA/SPEDRA. The company was founded by Virgil A. Place in April 16, 1991 and is headquartered in Campbell, CA. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.